The deal closure removes execution risk but the $70M cash outlay pressures near-term liquidity. Monitor Rigel's upcoming 10-Q for cash runway and initial VEPPANU revenue ramp. Milestone triggers and royalty start dates will be key catalysts.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $32.91entry
- T+1 · 5mo ago +8.57%α +8.88% · $35.73
- T+5 · 5mo ago +12.40%α +14.06% · $36.99
- T+20 · 4mo ago +26.62%α +26.09% · $41.67
- T+60 · 2mo ago +37.80%α +35.91% · $45.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. The deal closed following HSR clearance, with Rigel paying the $70 million upfront cash consideration. This milestone de-risks the transaction but provides no new financial terms beyond the original announcement.
Key Facts
- License agreement with Arvinas/Pfizer for VEPPANU (vepdegestrant) became effective on June 11, 2026.
- Company paid a one-time upfront payment of $70.0 million to the licensors upon closing.
- HSR waiting period terminated early and all other closing conditions satisfied.
- Rigel granted exclusive global rights to develop, manufacture and commercialize VEPPANU.
Financial Impact
$70.0 million upfront cash payment (approximately 11.6% of $601M market cap); additional contingent milestones up to $320M plus royalties and up to $40M development cost reimbursement per prior disclosure.
Risk Factors
- Significant upfront cash payment may strain balance sheet if VEPPANU revenue ramp is slow.
- Milestone payments and development cost reimbursements create future cash obligations beyond the upfront.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000043 |
| Document: 0001034842-26-000043-index.html | 0001034842-26-000043 |
| Document: 0001034842-26-000043.txt | 0001034842-26-000043 |
Track record
12 reports on RIGL
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Viewing Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers